# Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

Study · id `cardio:ct-nct03273322` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03273322](<https://clinicaltrials.gov/study/NCT03273322>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03273322

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT03273322. Randomized; no masking; primary purpose treatment. Start 2017-09-13 (actual); primary completion 2018-11-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT03273322, source copy `cardio:ctgov-nct03273322-2021-12-21`, retrieved 2026-10-26)
- Started: 2017-09-13 (actual) (ClinicalTrials.gov record NCT03273322, source copy `cardio:ctgov-nct03273322-2021-12-21`, retrieved 2026-10-26)
- Primary completion: 2018-11-20 (actual) (ClinicalTrials.gov record NCT03273322, source copy `cardio:ctgov-nct03273322-2021-12-21`, retrieved 2026-10-26)
- Completion: 2019-09-30 (actual) (ClinicalTrials.gov record NCT03273322, source copy `cardio:ctgov-nct03273322-2021-12-21`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT03273322, source copy `cardio:ctgov-nct03273322-2021-12-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03273322-2021-12-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
- Acronym: ADRIFT
- Condition: Atrial Fibrillation
- Condition: Atrial Appendage
- Condition: Hemorrhage
- Intervention (Drug): Rivaroxaban 10 mg qd
- Intervention (Drug): Rivaroxaban 15 mg qd
- Intervention (Drug): DAPT
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Action Research Group
- Collaborator class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Action Research Group (`cardio:org-action-research-group`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study (`cardio:pubmed-32674675`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d1bc60eceb235ce87cb6b08189ab173fbef7e932961ec8f8d7d6d9ddd7ce8269
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
